Slingshot Biosciences Announces Election of Nicolas Barthelemy as Executive Chair

2024-01-24

高管变更细胞疗法

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Slingshot Biosciences Inc., a leader in the development of cell mimics for cell therapy, diagnostics, and rare disease research, is proud to announce the addition of Nicolas Barthelemy as its Executive Chair. “We have been working closely with Nicolas over the last two years and are excited to bring his experience, operational expertise, and strategic insights to bear on this next phase of our growth,” said Dr. Jeffrey Kim - CEO & President of Slingshot Biosciences. Dr. Kim added, “He has been a trusted partner in getting the company to where it is, today, and will continue to be a key member of our extended team as we scale the business to help patients worldwide.” Mr. Barthelemy’s appointment comes at a crucial time as Slingshot is scaling its groundbreaking technologies in the biopharma sector, where he brings a long history of leadership in operating roles. His past experience includes Senior Management positions at leading companies in the sector, including Biogen and Life Technologies, where he held the position of Chief Commercial Officer. Nicolas also currently holds board positions at Repligen, Inc., Biocare Medical, and Nanocellect. “I am very excited to step-up my involvement with such a talented team at a pivotal time of its journey, and at the 'ground level' of a technology as potentially disruptive as Slingshot Biosciences' novel synthetic cells. With end-applications ranging from Research and Bioprocessing to Hematology, Diagnostics and Therapeutics, we have the opportunity to build a company that could meaningfully impact a very broad area of Life Sciences,” said Nicolas Barthelemy. Nicolas received an Engineering Degree from ESPCI (Paris, France) and an M.S. in Chemical Engineering from UC Berkeley. About Slingshot Biosciences At the cutting edge of cell engineering technology, Slingshot Biosciences is revolutionizing cell therapy development and manufacturing. The company’s pioneering work in creating cell mimics positions it uniquely to help advance research, diagnostics and biopharma manufacturing. Slingshot’s products offer more consistent, scalable, and ethically viable alternatives to traditional methods of cell-based sourcing. View source version on businesswire.com: Contacts Annalise Barnette pr@slingshotbio.com Source: Slingshot Biosciences Inc. View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构